デフォルト表紙
市場調査レポート
商品コード
1473972

造影マンモグラフィの世界市場規模、シェア、成長分析、用途別、エンドユーザー別- 産業予測、2024年~2031年

Global Contrast Enhanced Mammography Market Size, Share, Growth Analysis, By Applications(Screening and Diagnosis), By End User(Hospital, Diagnostic Centres) - Industry Forecast 2024-2031

出版日: | 発行: SkyQuest | ページ情報: 英文 219 Pages | 納期: 3~5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.89円
造影マンモグラフィの世界市場規模、シェア、成長分析、用途別、エンドユーザー別- 産業予測、2024年~2031年
出版日: 2024年04月29日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3~5営業日
  • 全表示
  • 概要
  • 目次
概要

造影マンモグラフィの世界市場規模は、2022年に18億4,000万米ドルと評価され、予測期間(2024-2031年)のCAGRは5.28%で、2023年の19億4,000万米ドルから2031年には29億2,000万米ドルに成長する見通しです。

デュアルエナジーアプローチを利用する造影マンモグラフィ(CEM)は、デジタルマンモグラフィの利点と静脈内造影剤投与を組み合わせたものです。CEMは、診断環境における乳がんの検出において、全視野デジタルマンモグラフィ(FFDM)単独や超音波と組み合わせたFFDMと比較して高い感度を示します。世界の乳がん罹患率の上昇に伴い、造影マンモグラフィ(CEM)は広く採用され、普及してきました。乳がんのリスク増加には、高齢化、肥満、過度の飲酒、乳がんの家族歴、過去の放射線被曝、生殖歴(初経年齢や出産年齢など)、タバコの使用、閉経後のホルモン療法など様々な要因が関与しています。乳がんの大部分は女性が罹患し、人口のかなりの部分を占め、通常は乳房組織から発生します。乳がんは、乳房のしこり、乳房の大きさや形の変化、乳頭からの分泌物、かゆみ、かさつき、発赤などの皮膚の変化など、さまざまな症状で現れます。さらに、進行すると骨の痛み、リンパ節の腫れ、呼吸困難などの症状が現れ、病気が広がっていきます。その結果、乳がんの世界の有病率の増加が、マーケット拡大のカタリストとなっています。

目次

エグゼクティブサマリー

  • 市場概要
  • 運命の輪

調査手法

  • 情報調達
  • 二次データソースと一次データソース
  • 市場規模の推定
  • 市場の危機と限界

親市場の分析

  • 市場概要
  • 市場規模
  • 市場力学
    • 促進要因
    • 機会
    • 抑制要因
    • 課題

主な市場の考察

  • 技術分析
  • 価格分析
  • サプライチェーン分析
  • バリューチェーン分析
  • 市場のエコシステム
  • IP分析
  • 貿易分析
  • スタートアップ分析
  • 原材料の分析
  • イノベーションマトリクス
  • パイプライン製品の分析
  • マクロ経済指標
  • 主な投資の分析
  • 主な成功要因
  • 競合の程度

市場力学と見通し

  • 市場力学
    • 促進要因
    • 機会
    • 抑制要因
    • 課題
  • 規制情勢
  • ポーターの分析
  • 将来の混乱についての特別な考察

造影マンモグラフィの世界市場:用途別

  • 市場概要
  • スクリーニングと診断

造影マンモグラフィの世界市場:エンドユーザー別

  • 市場概要
  • 病院
  • 診断センター
  • 専門クリニック
  • その他

造影マンモグラフィの世界市場規模:地域別

  • 市場概要
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • スペイン
    • フランス
    • 英国
    • その他の欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他のアジア太平洋
  • ラテンアメリカ
    • ブラジル
    • その他のラテンアメリカ
  • 中東・アフリカ(MEA)
    • GCC諸国
    • 南アフリカ
    • その他の中東・アフリカ

競合情勢

  • 上位5社の比較
  • 主要企業の市場ポジショニング(2023年)
  • 主な市場企業が採用した戦略
  • 主要成功戦略
  • 市場における最近の活動
  • 主要企業の市場シェア(2023年)

主要企業プロファイル

  • Hologic Inc.
  • GE Healthcare
  • Siemens Healthineers AG
  • Koninklijke Philips N.V.
  • Fujifilm Holdings Corporation
  • Dilon Technologies Inc.
  • Planmed Oy
  • Metaltronica S.p.A.
  • CMR Naviscan Corporation
  • General Medical Merate S.p.A.
  • Delphinus Medical Technologies Inc.
  • Micrima Limited
  • KUB Technologies Inc.
  • Aurora Imaging Technology Inc.
  • Carestream Health Inc.
  • Planmed Oy
  • Zebra Medical Vision Ltd.
  • Volpara Health Technologies Ltd.
  • iCAD Inc.
  • Agfa-Gevaert NV
  • In 2021, Hologic, Inc. announced the launch of its new CEM technology, the Quantra 3.0 Breast Density Assessment software, which uses artificial intelligence to provide more accurate and consistent breast density measurements.
  • In 2021, Siemens Healthineers announced the launch of its new MAMMOMAT Revelation with 3D biopsy technology, which combines CEM, 3D mammography,, biopsy in a single exam. The system is designed to improve accuracy, and reduce patient discomfort.
目次
Product Code: SQMIG35G2123

Global contrast enhanced mammography market size was valued at USD 1.84 billion in 2022 and is poised to grow from USD 1.94 billion in 2023 to USD 2.92 billion by 2031, at a CAGR of 5.28% during the forecast period (2024-2031)

Utilizing a dual-energy approach, contrast-enhanced mammography (CEM) combines the advantages of digital mammography with intravenous contrast administration. CEM exhibits higher sensitivity compared to full-field digital mammography (FFDM) alone and FFDM coupled with ultrasound in the detection of breast cancer within diagnostic settings. Given the escalating global incidence of breast cancer, contrast enhanced mammography (CEM) has emerged as a widely adopted and prevalent technique. Various factors contribute to the increased risk of breast cancer, including advancing age, obesity, excessive alcohol consumption, family history of breast cancer, past exposure to radiation, reproductive history (such as age at first menstruation and childbirth), tobacco usage, and postmenopausal hormone therapy. The majority of breast cancer cases predominantly affect females, impacting a significant portion of the population, usually originating in breast tissues. Breast cancer manifests through various symptoms, including breast lumps, alterations in breast size and shape, nipple discharge, as well as skin changes like itchiness, scaliness, and redness. Moreover, the progression of this disorder may result in additional symptoms such as bone pain, lymph node swelling, breathing difficulties, among others, signifying the spread of the disease. Consequently, the increasing prevalence of breast cancer globally serves as a catalyst for the expansion of the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the global contrast enhanced mammography market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Contrast Enhanced Mammography Market Segmental Analysis

Global contrast enhanced mammography market is segmented based on applications, end user, and region. By applications, the market is segmented into screening, and diagnosis. By end user, the market is segmented into hospital, diagnostic centres, specialty clinics, and others. By region, the market is segmented into North America, Europe, Asia-Pacific, South America, and MEA.

Drivers of the Global Contrast Enhanced Mammography Market

The primary driver of market growth is the increasing prevalence of breast cancer, which ranks as the most frequently diagnosed cancer among women globally. Early diagnosis significantly enhances the effectiveness of breast cancer treatment. Typically, patients undergo a combination of surgical procedures, radiation therapy, and medications like hormone therapy, chemotherapy, and targeted biological therapy to address microscopic cancer cells that may have spread from the original tumor. These treatments play a crucial role in halting the growth and spread of cancer, ultimately saving lives.

Restraints in the Global Contrast Enhanced Mammography Market

Contrast-enhanced mammography represents a newer technology in the field, accompanied by higher costs compared to traditional mammography. The expenses involved in acquiring equipment, materials, and providing necessary training for contrast-enhanced mammography pose significant barriers to its widespread adoption. Additionally, the availability of contrast-enhanced mammography remains limited, with a scarcity of facilities offering this technology, particularly in rural or remote areas. Regulatory approval is a prerequisite before contrast-enhanced mammography can be integrated into clinical practice, a process known for its lengthiness and expense, potentially delaying the technology's market entry. Furthermore, despite promising outcomes demonstrated in clinical studies, the absence of long-term data on its efficacy and safety may instill hesitation among healthcare providers regarding its adoption until more robust evidence becomes available.

Market Trends of the Global Contrast Enhanced Mammography Market

Each year witnesses a surge in breast cancer cases among women, driving the expansion of the market and the proliferation of available treatments. Advanced technologies have revolutionized breast cancer diagnostics, offering enhanced techniques for detection. These sophisticated technologies have significantly improved performance metrics such as efficiency, accuracy, efficacy, reliability, and speed of results, thereby facilitating early detection and intervention.

Table of Contents

Executive Summary

  • Market Overview
  • Wheel of Fortune

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Parent Market Analysis

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Regulatory Landscape
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
    • Political Impact
    • Economic Impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Global Contrast Enhanced Mammography Market by Applications

  • Market Overview
  • Screening and Diagnosis

Global Contrast Enhanced Mammography Market by End User

  • Market Overview
  • Hospital
  • Diagnostic Centres
  • Specialty Clinics
  • Others

Global Contrast Enhanced Mammography Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2023
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
    • By Development
    • By Company
    • By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2023

Key Company Profiles

  • Hologic Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GE Healthcare
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Siemens Healthineers AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Koninklijke Philips N.V.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Fujifilm Holdings Corporation
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Dilon Technologies Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Planmed Oy
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Metaltronica S.p.A.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • CMR Naviscan Corporation
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • General Medical Merate S.p.A.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Delphinus Medical Technologies Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Micrima Limited
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • KUB Technologies Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Aurora Imaging Technology Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Carestream Health Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Planmed Oy
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Zebra Medical Vision Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Volpara Health Technologies Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • iCAD Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Agfa-Gevaert NV
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • In 2021, Hologic, Inc. announced the launch of its new CEM technology, the Quantra 3.0 Breast Density Assessment software, which uses artificial intelligence to provide more accurate and consistent breast density measurements.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • In 2021, Siemens Healthineers announced the launch of its new MAMMOMAT Revelation with 3D biopsy technology, which combines CEM, 3D mammography, and biopsy in a single exam. The system is designed to improve accuracy and reduce patient discomfort.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments